Raymond James downgraded Korro Bio (KRRO) to Market Perform from Strong Buy without a price target after the Phase 1/2a REWRITE study showed KRRO-110 did not increase total alpha-1 antitrypsin above the protective threshold. The firm now sees a level of uncertainty associated with Korro’s overall platform.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: